Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc.
- Market cap
- $912.33M
Your view on ODTX
Overview
What the company does, where it operates, and who runs it.
About Odyssey Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gary D. Glick
- Headquarters
- 51 Sleeper Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gary D. Glick
- Headquarters
- 51 Sleeper Street, Boston, MA, US
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases.
Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis.
Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells.
Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Odyssey Therapeutics, Inc.. Starting points for Odyssey Therapeutics, Inc.: EPS -$3.71, beta 1.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Odyssey Therapeutics, Inc.. Trailing twelve-month EPS for Odyssey Therapeutics, Inc. stands at -$3.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
2 ratings- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$1.09 | −$1.18 | −$5.87 | −$4.44 |
| Lowest estimate | −$1.21 | −$1.26 | −$6.05 | −$4.88 |
| Highest estimate | −$1.01 | −$1.10 | −$5.77 | −$3.55 |
| Number of analysts | 4 | 3 | 5 | 6 |
| A year ago | — | −$6.771 | −$3.151 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $2.98M | $2.98M |
| Lowest estimate | $0.00 | $0.00 | $2.98M | $2.98M |
| Highest estimate | $0.00 | $0.00 | $2.98M | $2.98M |
| Number of analysts | 0 | 0 | 7 | 7 |
| A year ago | — | $0.00 | $2.98M | — |
| Growth vs a year ago | — | — | +0.0% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Odyssey Therapeutics, Inc.. Odyssey Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACRSAclaris Therapeutics, Inc. | Healthcare | Biotechnology | $555.1M | ||
| AGMBAgomAb Therapeutics N.V. American Depositary Shares | Healthcare | Biotechnology | $286.6M | ||
| ALMSAlumis Inc. Common Stock | Healthcare | Biotechnology | $568.9M | ||
| ANABAnaptysBio, Inc. | Healthcare | Biotechnology | $1.4B | ||
| IMUXImmunic, Inc. | Healthcare | Biotechnology | $102.6M | ||
| ORKAOruka Therapeutics, Inc. | Healthcare | Biotechnology | $6.5B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | Biotechnology | $8.3B | ||
| SYRESpyre Therapeutics, Inc. | Healthcare | Biotechnology | $9.6B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||
| PRAXPraxis Precision Medicines, Inc. | Healthcare | NASDAQ | $8.5B | ||
| PREDQPredictive Discovery Limited | Healthcare | OTC | $2,996 | ||
| PREV.CNPreveCeutical Medical Inc. | Healthcare | CNQ | $11.7M | ||
| PRLDPrelude Therapeutics Incorporated | Healthcare | NASDAQ | $191.0M | ||
| PRMEPrime Medicine, Inc. | Healthcare | NASDAQ | $694.9M | ||
| PRNAFAlterity Therapeutics Limited | Healthcare | OTC | $109.8M | ||
| PROKProKidney Corp. | Healthcare | NASDAQ | $349.7M | ||
| PROTProteonomix, Inc. | Healthcare | OTC | $791 | ||
| PRQRProQR Therapeutics N.V. | Healthcare | NASDAQ | $155.2M | ||
| PRRUFImmutep Limited | Healthcare | OTC | $368.0M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| VTWOVanguard Russell 2000 ETF | $16.6B in assets | 0.01% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.01% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
| AVSCAvantis U.S. Small Cap Equity ETF | $3.2B in assets | 0.01% | |
| VTWVVanguard Russell 2000 Value ETF | $1.3B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in ODTX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Odyssey Therapeutics, Inc., and how their positions are changing. At a $912.3M market value, institutional positions materially move Odyssey Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Odyssey Therapeutics, Inc.. Coverage tracks Odyssey Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Odyssey Therapeutics, Inc.